5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor (nicotinamide N-methyltransferase) that blocks fat storage, elevates NAD+ levels, and mimics caloric restriction effects. Research shows 7% body weight loss and muscle preservation in obese mice—without exercise/diet changes. Targets obesity, T2D, NAFLD, and aging via epigenetic/metabolic reprogramming.
Mechanism Edge: NNMT ↓ → SAM/SAH ratio shift → NAD+ ↑30–50%.
How It Works
- NNMT Inhibition: ↓Methylation of nicotinamide → NAD+ pool ↑.
- Fat Metabolism: ↓Adipogenesis, lipolysis ↑ in white fat.
- Mitochondrial Boost: SIRT1 activation → biogenesis.
- Anti-Fibrotic: ↓Collagen in liver/muscle.
Oral Bioavailability: High; half-life ~5h.
Research Evidence (Preclinical)
| Model (Dose) | Effects |
|---|---|
| Obese Mice (10mg/kg oral) | -7% BW, fat mass -40%, lean mass preserved (Front Endocrinol 2022). |
| Diet-Induced Obesity | Insulin sensitivity ↑2x, glucose tolerance normalized. |
| NAFLD | Liver TG -50%, inflammation ↓. |
| Aging | NAD+ ↑, endurance ↑ similar to CR. |
- Human Translation: Phase 1 prep; mouse-human equiv. 150–300mg/day.
Protocols (Research Contexts)
| Goal | Dose (mg/day) | Timing | Cycle |
|---|---|---|---|
| Fat Loss | 50–150 | Split TID w/ meals | 8–12 weeks |
| NAD+ Rejuvenation | 100–200 | AM/PM fasted | 12 weeks on/4 off |
| Metabolic Health | 75–100 | Daily | Ongoing |
| Stack | 100mg + NMN 500mg | Synergistic NAD | 8 weeks |
- Form: Capsules/powder; water-soluble.
Benefits Breakdown
- Weight Loss: Visceral fat target; no muscle catabolism.
- Energy/Mito: NAD+ fuels sirtuins/AMPs.
- Liver Health: Steatosis reversal.
- Performance: Endurance without AMPK crash.
- Anti-Aging: Epigenetic clock potential.
Side Effects & Safety
| Common (Mild) | Preclinical Notes | Mitigation |
|---|---|---|
| GI discomfort | None toxic | Low dose start |
| Headache | NNMT rebound? (low) | Hydrate |
- Tox: Clean LD50 >2g/kg.
- Status: Research chemical; no human trials (IND pending).
Comparisons: NNMT Inhibitors vs. NAD Boosters
| Compound | Target | Fat Loss | Oral? | Stage |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT | High | Yes | Preclinical |
| NMN/NR | NAMPT | Mod | Yes | Phase 2 |
| Resveratrol | SIRT1 | Low | Yes | Supplements |
| Metformin | AMPK | Mod | Yes | Approved |
Research Outlook
- Pipeline: Obesity trials 2025?; patents filed.
- UK: Academic/research only.
- Synergy: w/ Tirzepatide, exercise.
Disclaimer: Experimental—no human consumption.
| QUANTITY | 10mg, 50mg |
|---|
Reviews
There are no reviews yet.
Related products
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Be the first to review “5-Amino-1MQ”